Fresenius Medical Care AG & Co. KGaA (0H9X) Share Forecast & Price Target

Compare

3 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0H9X Analyst Ratings

Hold

3 Buy

4 Hold

5 Sell

Based on 12 analysts giving stock ratings to

Fresenius

Medical Care AG & Co. KGaA

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0H9X Stock 12 Month Forecast

Average Price Target

€45.26

▲(11.07% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for Fresenius Medical Care AG & Co. KGaA in the last 3 months. The average price target is €45.26 with a high forecast of €60.00 and a low forecast of €35.00. The average price target represents a 11.07% change from the last price of €40.75.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"34":"€34","61":"€61","40.75":"€40.8","47.5":"€47.5","54.25":"€54.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€60.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":45.26,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€45.26</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€35.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[34,40.75,47.5,54.25,61],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,40.99,42.45230769230769,43.91461538461539,45.37692307692308,46.83923076923077,48.30153846153846,49.76384615384615,51.22615384615385,52.68846153846154,54.15076923076923,55.613076923076925,57.075384615384614,58.53769230769231,{"y":60,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,40.99,41.31846153846154,41.64692307692308,41.97538461538462,42.30384615384615,42.63230769230769,42.96076923076923,43.28923076923077,43.61769230769231,43.94615384615385,44.27461538461538,44.60307692307692,44.93153846153846,{"y":45.26,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,40.99,40.52923076923077,40.06846153846154,39.60769230769231,39.14692307692308,38.68615384615385,38.22538461538461,37.76461538461538,37.30384615384615,36.84307692307692,36.38230769230769,35.92153846153846,35.46076923076923,{"y":35,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":41.77,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":42.95,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":46.86,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":45,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":44.8,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":43.29,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":50.4,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":48.64,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":43.28,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":44.04,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":45.28,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":46.56,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":40.99,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€60.00

Average Price Target€45.26

Lowest Price Target€35.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Aisyah Noor

Morgan Stanley

€39→€37

Sell

-9.20%

Downside

Reiterated

12/15/25

Fresenius Medical price target lowered to EUR 37 from EUR 39 at Morgan StanleyFresenius Medical price target lowered to EUR 37 from EUR 39 at Morgan Stanley

Anna Ractliffe

Bank of America Securities

€38→€35

Sell

-14.11%

Downside

Reiterated

12/11/25

Cautious Outlook for Fresenius Medical Care Amid Sector Challenges and Persistent Headwinds

David Adlington

J.P. Morgan

€41.5→€37.4

Sell

-8.22%

Downside

Reiterated

12/08/25

Fresenius Medical price target lowered to EUR 37.40 from EUR 41.50 at JPMorganFresenius Medical price target lowered to EUR 37.40 from EUR 41.50 at JPMorgan

Sam England

Berenberg Bank

€60

Buy

47.24%

Upside

Reiterated

12/03/25

Fresenius Medical Care AG & Co. KGaA (0H9X) Receives a Buy from Berenberg Bank

Graham Doyle

UBS

€38

Sell

-6.75%

Downside

Reiterated

12/01/25

UBS Sticks to Their Sell Rating for Fresenius Medical Care AG & Co. KGaA (0H9X)

Hassan Al-Wakeel

Barclays

€51→€48

Hold

17.79%

Upside

Reiterated

11/24/25

Barclays Sticks to Their Hold Rating for Fresenius Medical Care AG & Co. KGaA (0H9X)

Oliver Reinberg

Kepler Capital

€49

Hold

20.25%

Upside

Reiterated

11/16/25

Richard Felton

Goldman Sachs

€60→€55

Buy

34.97%

Upside

Reiterated

11/07/25

Fresenius Medical Care AG & Co. KGaA (0H9X) Receives a Buy from Goldman Sachs

Unknown Analyst

DZ BANK AG

Not Ranked

DZ BANK AG

Buy

―

Reiterated

11/05/25

Falko Friedrichs

Deutsche Bank

€48

Hold

17.79%

Upside

Reiterated

11/05/25

Deutsche Bank Reaffirms Their Hold Rating on Fresenius Medical Care AG & Co. KGaA (0H9X)

James Vane

Jefferies

€36

Sell

-11.66%

Downside

Reiterated

11/04/25

Jefferies Keeps Their Sell Rating on Fresenius Medical Care AG & Co. KGaA (0H9X)

Lisa Bedell Clive

Bernstein

€54.5

Hold

33.74%

Upside

Reiterated

10/20/25

Bernstein Reaffirms Their Hold Rating on Fresenius Medical Care AG & Co. KGaA (0H9X)

Veronika Dubajova

Citi

€46.5→€52.5

Hold

28.83%

Upside

Reiterated

06/05/25

Fresenius Medical Care AG & Co. KGaA (0H9X) Receives a Hold from Citi

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Aisyah Noor

Morgan Stanley

€39→€37

Sell

-9.20%

Downside

Reiterated

12/15/25

Fresenius Medical price target lowered to EUR 37 from EUR 39 at Morgan StanleyFresenius Medical price target lowered to EUR 37 from EUR 39 at Morgan Stanley

Anna Ractliffe

Bank of America Securities

€38→€35

Sell

-14.11%

Downside

Reiterated

12/11/25

Cautious Outlook for Fresenius Medical Care Amid Sector Challenges and Persistent Headwinds

David Adlington

J.P. Morgan

€41.5→€37.4

Sell

-8.22%

Downside

Reiterated

12/08/25

Fresenius Medical price target lowered to EUR 37.40 from EUR 41.50 at JPMorganFresenius Medical price target lowered to EUR 37.40 from EUR 41.50 at JPMorgan

Sam England

Berenberg Bank

€60

Buy

47.24%

Upside

Reiterated

12/03/25

Fresenius Medical Care AG & Co. KGaA (0H9X) Receives a Buy from Berenberg Bank

Graham Doyle

UBS

€38

Sell

-6.75%

Downside

Reiterated

12/01/25

UBS Sticks to Their Sell Rating for Fresenius Medical Care AG & Co. KGaA (0H9X)

Hassan Al-Wakeel

Barclays

€51→€48

Hold

17.79%

Upside

Reiterated

11/24/25

Barclays Sticks to Their Hold Rating for Fresenius Medical Care AG & Co. KGaA (0H9X)

Oliver Reinberg

Kepler Capital

€49

Hold

20.25%

Upside

Reiterated

11/16/25

Richard Felton

Goldman Sachs

€60→€55

Buy

34.97%

Upside

Reiterated

11/07/25

Fresenius Medical Care AG & Co. KGaA (0H9X) Receives a Buy from Goldman Sachs

Unknown Analyst

DZ BANK AG

Not Ranked

DZ BANK AG

Buy

―

Reiterated

11/05/25

Falko Friedrichs

Deutsche Bank

€48

Hold

17.79%

Upside

Reiterated

11/05/25

Deutsche Bank Reaffirms Their Hold Rating on Fresenius Medical Care AG & Co. KGaA (0H9X)

James Vane

Jefferies

€36

Sell

-11.66%

Downside

Reiterated

11/04/25

Jefferies Keeps Their Sell Rating on Fresenius Medical Care AG & Co. KGaA (0H9X)

Lisa Bedell Clive

Bernstein

€54.5

Hold

33.74%

Upside

Reiterated

10/20/25

Bernstein Reaffirms Their Hold Rating on Fresenius Medical Care AG & Co. KGaA (0H9X)

Veronika Dubajova

Citi

€46.5→€52.5

Hold

28.83%

Upside

Reiterated

06/05/25

Fresenius Medical Care AG & Co. KGaA (0H9X) Receives a Hold from Citi

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Fresenius Medical Care AG & Co. KGaA

1 Month

xxx

Success Rate

24/52 ratings generated profit

Average Return

-1.59%

reiterated a xxx

rating 10 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 46.15% of your transactions generating a profit, with an average return of -1.59% per trade.

3 Months

xxx

Success Rate

0/0 ratings generated profit

Average Return

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in - of your transactions generating a profit, with an average return of - per trade.

1 Year

James VaneJefferies

Success Rate

27/47 ratings generated profit

Average Return

-2.56%

reiterated a sell rating 2 months ago

Copying James Vane's trades and holding each position for 1 Year would result in 57.45% of your transactions generating a profit, with an average return of -2.56% per trade.

2 Years

xxx

Success Rate

24/47 ratings generated profit

Average Return

-5.23%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 51.06% of your transactions generating a profit, with an average return of -5.23% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0H9X Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0H9X has received 3 Buy Ratings, 7 Hold Ratings, and 13 Sell Ratings. 0H9X average Analyst price target in the past 3 months is 45.26.

Each month's total comprises the sum of three months' worth of ratings.

0H9X Financial Forecast

0H9X Earnings Forecast

Next quarter’s earnings estimate for 0H9X is €1.03 with a range of €0.77 to €1.34. The previous quarter’s EPS was €1.10. 0H9X beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year 0H9X has Performed in-line its overall industry.

0H9X Sales Forecast

Next quarter’s sales forecast for 0H9X is €4.81B with a range of €3.92B to €5.15B. The previous quarter’s sales results were €4.88B. 0H9X beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year 0H9X has Performed in-line its overall industry.

0H9X Stock Forecast FAQ

What is GB:0H9X’s average 12-month price target, according to analysts?

Based on analyst ratings, Fresenius Medical Care AG & Co. KGaA’s 12-month average price target is 45.26.

What is GB:0H9X’s upside potential, based on the analysts’ average price target?

Fresenius Medical Care AG & Co. KGaA has 11.07% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Fresenius Medical Care AG & Co. KGaA a Buy, Sell or Hold?

Fresenius Medical Care AG & Co. KGaA has a consensus rating of Hold, which is based on 3 buy ratings, 4 hold ratings and 5 sell ratings.

What is Fresenius Medical Care AG & Co. KGaA’s share price target?

The average share price target for Fresenius Medical Care AG & Co. KGaA is 45.26. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €60.00 ,and the lowest forecast is €35.00. The average share price target represents 11.07% Increase from the current price of €40.75.

What do analysts say about Fresenius Medical Care AG & Co. KGaA?

Fresenius Medical Care AG & Co. KGaA’s analyst rating consensus is a Hold. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of Fresenius Medical Care AG & Co. KGaA?

To buy shares of GB:0H9X, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Fresenius Medical Care AG & Co. KGaA (0H9X) Share Forecast & Price Target

0H9X Analyst Ratings

0H9X Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Fresenius Medical Care AG & Co. KGaA

0H9X Analyst Recommendation Trends

0H9X Financial Forecast

0H9X Earnings Forecast

0H9X Sales Forecast

0H9X Stock Forecast FAQ

Detailed List of Analyst Forecasts